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Abstract: Deciphering how signaling pathways interact during development is necessary for
understanding the etiopathogenesis of congenital malformations and disease. In several embryonic
structures, components of the Hedgehog and retinoic acid pathways, two potent players in
development and disease are expressed and operate in the same or adjacent tissues and cells.
Yet whether and, if so, how these pathways interact during organogenesis is, to a large extent, unclear.
Using genetic and experimental approaches in the mouse, we show that during development of
ontogenetically different organs, including the tail, genital tubercle, and secondary palate, Sonic
hedgehog (SHH) loss-of-function causes anomalies phenocopying those induced by enhanced retinoic
acid signaling and that SHH is required to prevent supraphysiological activation of retinoic signaling
through maintenance and reinforcement of expression of the Cyp26 genes. Furthermore, in other
tissues and organs, disruptions of the Hedgehog or the retinoic acid pathways during development
generate similar phenotypes. These findings reveal that rigidly calibrated Hedgehog and retinoic
acid activities are required for normal organogenesis and tissue patterning.
Keywords: Cyp26 enzymes; congenital anomalies; CRE/LoxP; hedgehog signaling; mouse models;
retinoic acid; smoothened; sonic hedgehog
1. Introduction
Development and homeostasis of multicellular organisms crucially rely on concerted functions of
a multitude of proteins and small molecules that operate within signaling pathways. Understanding
how signaling pathways interact to ensure normal embryonic development and maintenance of
proper shape, size, cellular organization and function of tissues and organs is requisite to decipher the
etiopathogenesis of congenital malformations and diseases.
Int. J. Mol. Sci. 2019, 20, 2275; doi:10.3390/ijms20092275 www.mdpi.com/journal/ijms
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The Hedgehog and retinoic acid (RA) signaling pathways play key roles during embryogenesis,
organogenesis, and tissue homeostasis [1–13], and genetic disruption of Hedgehog signaling can
lead to neoplasia [1,14–18]. Mammals produce three Hedgehog ligands, Desert hedgehog, Indian
hedgehog (IHH) and Sonic hedgehog (SHH) [1,19]. Hedgehog ligands, notably SHH and IHH proteins,
emanating from producing cells, can signal both short and long-range [1,4]. The Hedgehog signaling
cascade is regulated by several factors at different levels, from ligand modifications and release to
ligand reception and signal transduction [4,6]. In the absence of Hedgehog ligands, the Hedgehog
receptor PTCH1 accumulates predominantly in the primary cilium and inhibits Smoothened (SMO),
an obligatory factor for the transduction of all Hedgehog signals, leading to the formation of repressor
forms of GLI transcription factors that repress Hedgehog target genes. Upon ligand binding to PTCH1,
the activated SMO protein translocates to the cilium and initiates a signaling cascade that reaches its
acme in the nucleus, where the activator forms of GLI proteins activate transcription of Hedgehog
target genes. The principal GLI activator function derives primarily from GLI2, whereas the GLI
repressor function largely emanates from GLI3 [1,4,6,18,20,21].
All-trans retinoic acid (RA), the predominant active metabolite of the dietary-derived vitamin A,
is a small, highly diffusible and biologically potent lipophilic molecule. During embryonic development,
RA is produced from maternally-derived vitamin A. Experimental studies in rodents and avians
established the importance of vitamin A for proper development, as vitamin A deficiency during
embryogenesis and early organogenesis engenders a wide range of congenital anomalies [22]. However,
exposure of embryos to excess vitamin A or RA is teratogenic. Direct evidence for the crucial role of RA
during development emanated from genetic gain and loss-of-function studies in mice and zebrafish,
which demonstrated that proper tissue patterning and cell fate specification require well-calibrated
spatio-temporal RA activity [2,3,5,23,24].
RA synthesis from retinol, the alcohol form of vitamin A, is a stepwise process catalyzed by
various dehydrogenases. First, retinol is oxidized into retinaldehyde by alcohol dehydrogenases and
retinol dehydrogenases. Thereafter, oxidation of retinaldehyde to RA is catalyzed by retinaldehyde
dehydrogeneases, including RALDH1, RALDH2, and RALDH3, encoded by Aldh1a1, Aldh1a2 and
Aldh1a3, respectively [2,22,24]. RA is degraded by the cytochrome P450 isoenzymes CYP26A1 [25],
CYP26B1 [26], and CYP26C1 [27]. Thus, cells expressing CYP26 enzymes are protected from
physiological RA activity. RA signaling is mediated by heterodimers of two classes of DNA-binding
nuclear receptors that bind to RA response elements (RARE) to regulate target gene transcription: (1)
the retinoic acid receptors (RARα, RARβ, and RARγ encoded by RARa, RARb and RARg, respectively)
which bind to all-trans RA and (2) the retinoid X receptors (RXRα, RXRβ, and RXRγ encoded by RXRa,
RXRb and RXRg, respectively) that bind to 9-cis-RA. In the absence of ligand, RAR/RXR dimers recruit
co-repressors to inhibit transcription of RA target genes, whereas ligand-bound RAR/RXR dimers
recruit co-activators to activate the same targets [2,22,24].
Previous studies have shown that cells can respond to both SHH and RA signaling, and that
coordinated functions of these pathways are required for normal development. In this respect, during
patterning of the spinal cord, SHH and RA exhibit complementary roles in specification of motor
neuron progenitor identity [28–30]. Likewise, the SHH and RA pathways converge to influence other
developmental processes, including patterning and differentiation of the forebrain, early specification
of neuronal and mesodermal derivatives, and the establishment of left-right asymmetry [1,31–36]. RA
and Hedgehog activities may also directly control expression of the same target genes, as exemplified
by the existence of functional GLI and RAR-RXR binding sites in the Ngn2 enhancer [37]. However,
in other biological settings SHH has been shown to oppose RA activity. In the developing limb for
example, SHH operates within a signaling network to promote proximal-distal growth by enhancing
CYP26B1-mediated RA degradation [38]. In the human bone marrow, multiple myeloma cells modify
their microenvironment to escape differentiation and reinforce chemoprotection by inhibiting RA
activity in the stroma through SHH-mediated upregulation of CYP26A1 expression [39].
Int. J. Mol. Sci. 2019, 20, 2275 3 of 27
Recently, we showed that in the developing tongue antagonistic activities of SHH and RA control
patterning, growth and epithelial cell fate specification and that SHH inhibits RA inputs through
maintenance and enhancement of Cyp26a1 and Cyp26c1 expression in the lingual epithelium [40].
While reviewing the literature pertaining to the RA and Hedgehog signaling pathways, we noticed that
in several tissues and organs loss of Hedgehog signaling generates malformations that are strikingly
similar to those engendered by supraphysiological activation of RA signaling. We therefore sought
to determine whether in murine tissues known to depend on SHH for normal development, SHH
antagonizes RA signaling through CYP26. To this end, we used mutant mice lacking SHH signaling
and complementary experimental approaches in vitro. We found that loss of SHH signaling causes
indeed loss of expression of Cyp26 genes and enhancement of RA signaling during ontogeny of organs
as disparate as craniofacial structures, genital tubercle and tail, and generates anomalies mimicking
those engendered by genetically or pharmacologically induced activation of RA signaling. These
findings show that in different developing organs SHH signaling uses a common strategy to antagonize
RA activity. Our findings provide a concept to further the understanding of the pathogenesis of
congenital malformations caused by altered Hedgehog signaling and the mechanisms underlying
Hedgehog-dependent tumorigenesis.
2. Results and Discussion
To determine whether, as in the developing tongue [40], SHH signaling also impinges upon RA
activity in other embryonic structures, we generated and studied K14-CRE/Shhf/f mutant embryos,
in which the Shh gene is disabled in Keratin-14 expressing cells and their progeny [40,41], as well
as ShhGFPCRE/Smof/f and ShhCreERT2/Shhf mutant embryos, which lack the function of the Smo and
Shh genes, respectively, in cells that express Shh and their progeny [40–43]. In the ShhGFPCRE/Smof/f
mutants, only cells that express or have expressed SHH are unable to respond to SHH signaling. In the
ShhCreERT2/Shhf mutants exposure to tamoxifen (TAM) abrogates SHH production, leading to loss of
both autocrine and paracrine SHH signaling. Similary, in the K14-CRE/Shhf/f mutants, both autocrine
and paracrine SHH signaling are disabled. Embryos not expressing the CRE gene and/or the floxed
Smo and Shh alleles were phenotypically normal; they were thus used as controls [40–42].
2.1. SHH Signaling Antagonizes RA Activity through CYP26A1 to Ensure Proper Development of the Tail
Experimental and genetic studies have demonstrated that SHH emanating from the notochord,
a mesodermal midline rod-like structure, and the neural floor plate is required for survival and expansion
of the sclerotomes, somite-derived structures that form the vertebral column [1,44]. Homozygous Shh
null (Shhn/n) mutant embryos, in which Shh is disabled in the germ line exhibit severe axial defects
with nearly total absence of sclerotomal derivatives, including the entire vertebral column [44]. In the
Shhn/n mutants, the notochord differentiates, but is subsequently lost, indicating that autocrine SHH
signaling is essential for maintenance of this important structure [44]. After fulfilling its function in
patterning adjacent tissues, the notochord persists only in prospective intervertebral discs, where it
develops into the nucleus pulposus. ShhGFPCRE/Smof/f and TAM-induced ShhCreERT2/Shhf mutants,
in which abrogation of SHH signaling occurs shortly after formation of the notochord and floor plate,
exhibit an abnormally thin notochord and lack intervertebral discs in the thoracic and lumbar regions.
The latter anomaly is due to loss of notochordal integrity, leading to failure of development of the
nucleus pulposus [42].
Shhn/n, ShhGFPCRE/Smof/f and TAM-induced ShhCreERT2/Shhf mutants all display a severely
truncated and abnormally thin tail totally lacking vertebrae [42,44] (see also Figure 1A–G).
Furthermore, immunostaining for SHH and Keratin 8, molecular markers of the notochord and
nucleus pulposus [42,45,46], showed that in contrast to control tails which exhibited a notochord, the
mutants tails were devoid of this structure, except rostrally, where an abnormally thin Keratin 8-positive
notochord was detectable (Figure 1H–O). Development of vertebrae is heralded by condensation
of sclerotome-derived chondrogenic mesenchymal cells. These structures failed to develop in the
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mutant tails (Figure 1H–O), consistent with failure of development of tail vertebrae upon loss of SHH
signaling [42,44].
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Figure 1. Loss of sonic hedgehog (SHH) signaling generates an abnormally thin and truncated tail 
lacking the notochord and vertebral chondrogenic condensations. (A–G). Representative external tail 
phenotype (arrows) of mutants relative to controls. Control (A; n = 15), ShhGFPCRE/Smof/f mutant (B; 
n = 11), and Shhn/n mutant (C; n = 2) newborns (P0). E17.5 control (D; n = 8) and ShhCreERT2/Shhf 
mutant (E; n = 9) embryos first exposed to tamoxifen (TAM) at E11.5. E14.5 control (F; n = 5) and 
ShhCreERT2/Shhf mutant (G; n = 6) embryos first exposed to TAM at E10.5. The mutants exhibit severe 
tail defects. (H–O) Tail sections from E15.5 mutants and controls immunostained (dark purple) for 
Keratin 8 (K8) and Sonic hedgehog (SHH) to visualize the notochord. Tails from a control embryo 
(H,J) and a ShhGFPCRE/Smof/f embryo (I,K). Tails from a control embryo (L,N) and a ShhCreERT2/Shhf 
mutant embryo (M,O) first exposed to TAM at E10.5. The control tails display chondrogenic 
mesenchymal condensations of presumptive vertebrae (asterisks) and a notochord (arrows) in the 
caudal region, whereas the mutant tails lack these structures. K8-positive (arrows in I and M) 
remnants of the notochord are visible in the rostral region of the mutant tails. HF, hair follicle. Scale 
bars: 2 mm (A–C), 1 mm (D–G) and 200 µm (H–O). 
Tail development initiates in the future lumbosacral region and coincides with the closure of 
the posterior neuropore. Tail tissues, including the neural tube, notochord and somites, originate 
from the tail bud mesenchyme, a progenitor zone located at the tip of the embryonic tail. The 
hindgut extends a short distance into the elongating tail after closure of the posterior neuropore [47]. 
The developing tail expresses components of the SHH and RA pathways. SHH is produced in the 
notochord and neural floor plate and elicits responses in the notochord, neuroepithelium, as well as 
in somites and sclerotomes [1,42]. Aldh1a2 is expressed in presomitic and somitic mesoderm anterior 
to the tail bud [22,48,49], whereas RARs are expressed in presomitic and somitic mesoderm, 
sclerotomes, and tail bud [22,47,50–52]. RA signaling is tightly controlled by the activities of 
Figure 1. Loss of sonic hedgehog (SHH) signaling generates an abnormally thin and truncated tail
lacking the notochord and vertebral chondrogenic condensations. (A–G). Representative external tail
phenotype (arrows) of mutants relative to controls. Control (A; n = 15), ShhGFPCRE/Smof/f mutant
(B; n = 11), and Shhn/n mutant (C; n = 2) newborns (P0). E17.5 control (D; n = 8) and ShhCreERT2/Shhf
mutant (E; n = 9) embryos first exposed to tamoxifen (TAM) at E11.5. E14.5 control (F; n = 5) and
ShhCreERT2/Shhf mutant (G; n = 6) embryos first exposed to TAM at E10.5. The mutants exhibit severe
tail defects. (H–O) Tail sections from E15.5 mutants and controls immunostained (dark purple) for
Keratin 8 (K8) and Sonic hedgehog (SHH) to visualize the notochord. Tails from a control embryo (H,J)
and a ShhGFPCRE/Smof/f embryo (I,K). Tails from a control embryo (L,N) and a ShhCreERT2/Shhf mutant
embryo (M,O) first exposed to TAM at E10.5. The control tails display chondrogenic mesenchymal
condensations of presumptive vertebrae (asterisks) and a notochord (arrows) in the caudal region,
whereas the mutant tails lack these structures. K8-positive (arrows in I and M) remnants of the
notochord are visible in the rostral region of the mutant tails. HF, hair follicle. Scale bars: 2 mm (A–C),
1 mm (D–G) and 200 µm (H–O).
Tail development initiates in the future lumbosacral region and coincides with the closure of the
posterior neuropore. Tail tissues, including the neural tube, notochord and somites, originate from the
tail bud mesenchyme, a progenitor zone located at the tip of the embryonic tail. The hindgut extends a
short distance into the elongating tail after closure of the posterior neuropore [47]. The developing
tail expresses components of the SHH and RA pathways. SHH is produced in the notochord and
neural floor plate and elicits responses in the notochord, neuroepithelium, as well as in somites and
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sclerotomes [1,42]. Aldh1a2 is expressed in presomitic and somitic mesoderm anterior to the tail
bud [22,48,49], whereas RARs are expressed in presomitic and somitic mesoderm, sclerotomes, and tail
bud [22,47,50–52]. RA signaling is tightly controlled by the activities of RALDHs and CYP26s, and
loss-of-function of CYP26s during development leads to supraphysiological activation of RA signaling
with entailing congenital malformations [53,54]. In the embryonic tail, Cyp26a1 is expressed at high
levels in the tail bud mesoderm, the neuroepithelium and hindgut endoderm [25,55–58].
Remarkably, the tail phenotype characterized by formation of a truncated and thin tail lacking
vertebrae in the Shhn/n, ShhGFPCRE/Smof/f and TAM-induced ShhCreERT2/Shhf mutants is strikingly
similar to that in Cyp26a1n/n mice [25,59,60] and rodent embryos exposed to teratogenic doses of vitamin
A or RA [61–65]. Furthermore, exposure of hamster embryos to exogenous RA causes degeneration
of the notochord and alters the formation of axial chondrogenic condensations [66], mimicking the
anomalies caused by loss of SHH signaling. Cyp26b1 and Cyp26c1 are not expressed during the critical,
SHH-dependent stages of tail formation [57,67] and embryos with loss-of-function of Cyp26b1 [26,68]
and Cyp26c1 [27] do not exhibit tail truncation. Cyp26b1 transcripts become detectable at later
developmental stages concomitantly with the formation of chondrogenic mesenchymal condensations
prefiguring vertebrae [69]. These become visible in the proximal part of the caudal region of mouse
embryos at E12.5-E13 [70]. It is noteworthy that chondrogenic mesenchymal condensations express
Indian Hedgehog [71,72]. These observations may be taken to suggest that the tail defects engendered
by loss of SHH signaling are caused, at least in part, by abnormal activation of RA signaling owing to
loss CYP26A1-mediated RA degradation.
To explore this possibility, we assessed the expression levels of RARb and RARg, well-established
direct transcriptional targets of RA signaling [23], as well as the expression patterns of Cyp26a1 in control
and mutant tails. Reverse transcription quantitative PCR (RT-qPCR) revealed significant upregulation
of RARb and RARg transcripts in tails from ShhGFPCRE/Smof/f and TAM-induced ShhCreERT2/Shhf
mutants (Figure 2J,K). Furthermore, Cyp26a1 in situ hybridization signals were either abolished or
dramatically diminished in the mutant tails (Figure 2A–I).
RA activity can be visualized in tissues from mice carrying the RAREhsplacZ transgene [73].
Although this transgene fails to accurately reveal RA activity in several tissues and organs, including
the developing tongue [40,73–76] and a large part of the palatal shelves of the secondary palate [77],
it is able to visualize abnormal activation of RA signaling in the developing tail [59,60]. We thus took
advantage of this possibility by examining tails from controls and ShhGFPCRE/Smof/f mutants carrying
the RAREhsplacZ transgene and found that similar to Cyp26a1n/n embryos [60] the ShhGFPCRE/Smof/f
mutants exhibited expansion of RAREhsplacZ activity in the developing tail (Figure 2L–O), indicating
ectopic activation of RA signaling. Taken together, these findings show that loss of SHH signaling in
the developing tail causes a decrease of Cyp26a1 expression and enhancement of RA signaling.
Recently, we showed that in the developing tongue, SHH activity is required for maintenance and
reinforcement of Cyp26a1 and Cyp26c1 expression but not for the initiation of their expression [40].
This phenomenon occurs also in the developing tail, since in vitro treatment of tails with SAG, a SMO
agonist enhanced the intensity of Cyp26a1 hybridization signals in tails but failed to induce ectopic
Cyp26a1 expression in adjacent tissues (Figure 2P,Q).
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Figure 2. Loss of SHH signaling in the developing tail causes loss of Cyp26a1 expression and ectopic 
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with riboprobes showing Cyp26a1 expression (purple) in developing tails. E9.5-E10 control (A; n = 3) 
and ShhCreERT2/Shhf mutant (B; n = 4) embryos first exposed to tamoxifen (TAM) at E8-E8.5. Control 
(C,E) and ShhGFPCRE/Smof/f mutant (D,F,G) embryos at E10.5 (C,D; n = 4 controls and n = 4 mutants) 
and E11.5 (E–G; n = 4 controls and n = 3 mutants). In the control tails, the Cyp26a1 expression domain 
extends from the tail bud to more rostral levels of the tail (arrowheads in A,C and E). The mutant 
tails exhibit either a severely reduced domain of Cyp26a1 expression (arrowheads in D and F) or 
abolished Cyp26a1 expression (arrows in B and G). (H,I) Representative tail sections from E11 control 
embryos (H; n = 2) and a ShhGFPCRE/Smof/f mutant embryo (I) after ISH for Cyp26a1 with 
oligonucleotide probes (black). Decreased Cyp26a hybridization signals in the mutant tail as 
compared to the control tail (arrowheads in H and I). (J,K) RT-qPCR analysis showing the expression 
levels of RARb and RARg relative to Actb (β-actin). Upregulation of RARb (p = 0.0162) and RARg (p = 
0.0261) levels in tails from E13.5 ShhCreERT2/Shhf mutant (n = 3 and n = 4 for RARb and RARg 
analyses, respectively) as compared to tails from control (n = 3 and n = 4 for RARb and RARb 
analyses, respectively) embryos first exposed to TAM at E11.5 (J). Upregulation of RARb (p = 0.0476) 
Figure 2. Loss of SHH signaling in the developing tail causes loss of Cyp26a1 expression and ectopic
activation of retinoic acid signaling. (A–G) Representative whole-mount in situ hybridization (ISH)
with riboprobes showing Cyp26a1 expression (purple) in developing tails. E9.5-E10 control (A; n = 3)
and ShhCreERT2/Shhf mutant (B; n = 4) embryos first exposed to tamoxifen (TAM) at E8-E8.5. Control
(C,E) and ShhGFPCRE/Smof/f mutant (D,F,G) embryos at E10.5 (C,D; n = 4 controls and n = 4 mutants)
and E11.5 (E–G; n = 4 controls and n = 3 mutants). In the control tails, the Cyp26a1 expression domain
extends from the tail bud to more rostral levels of the tail (arrowheads in A,C and E). The mutant tails
exhibit either a severely reduced domain of Cyp26a1 expression (arrowheads in D and F) or abolished
Cyp26a1 expression (arrows in B and G). (H,I) Representative tail sections from E11 control embryos (H;
n = 2) and a ShhGFPCRE/Smof/f mutant embryo (I) after ISH for Cyp26a1 with oligonucleotide probes
(black). Decreased Cyp26a hybridization signals in the mutant tail as compared to the control tail
(arrowheads in H and I). (J,K) RT-qPCR analysis showing the expression levels of RARb and RARg
relative to Actb (β-actin). Upregulation of RARb (p = 0.0162) and RARg (p = 0.0261) levels in tails from
E13.5 ShhCreERT2/Shhf mutant (n = 3 and n = 4 for RARb and RARg analyses, respectively) as compared
to tails from control (n = 3 and n = 4 for RARb and RARb analyses, respectively) embryos first exposed
to TAM at E11.5 (J). Upregulation of RARb (p = 0.0476) and RARg (p = 0.0610) levels in tails from E12.5
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ShhGFPCRE/Smof/f mutants (n = 3 and n = 4 for RARb and RARg analyses, respectively) as compared
to tails from controls (n = 3 and n = 4 for RARb and RARg analyses, respectively) (K). Data are mean
values ± standard deviation; *: p < 0.05. (L–O) Representative β-galactosidase (β-gal) histochemistry
visualizing retinoic acid activity (blue) in control (L,N) and ShhGFPCRE/Smof/f mutant (M,O) embryos
carrying the RAREhsplacZ transgene (RARElacZ) at E10 (L,M; n = 3 controls and n = 3 mutants) and
at E11 (N,O; n = 7 controls and n = 3 mutants). The mutants exhibit ectopic retinoic acid activity
(arrows in M and O) in tail tissues. s, somite. (P,Q) Representative tail explants from E11.5 control
embryos treated for 24 h with DMSO (P; n = 5) and 0.2 µM SAG (Q; n = 4) showing expansion of
Cyp26a1 expression domain (arrowheads in P and Q) and increased Cyp26a1 hybridization signals in
the SAG-treated tail and failure of SAG to induce ectopic Cyp26a1 expression in adjacent structures,
including the hindlimb bud (lb). Scale bars: 300 µm (A–G,L–Q) and 100 µm (H,I).
To determine whether increased RA signaling is indeed involved in the genesis of tail anomalies
upon loss of SHH signaling, we cultured tails from TAM-treated ShhCreERT2/Shhf mutant and control
embryos (Figure 3A) in the presence of BMS493, a RA signaling inhibitor, or DMSO (control vehicle).
Compared to tails from control embryos, the DMSO-treated mutant tails exhibited an abnormally thin
notochord in the rostral region and were devoid of notochord in the posterior region (Figure 3B–3D’).
However, the BMS493-treated mutant tails exhibited an intact notochord (Figure 3E,E’), indicating that
degeneration of the notochord was prevented upon inhibition of RA signaling. These data suggest that
RA signaling participates in the degeneration of the caudal notochord upon loss of SHH signaling.
However, compared to tails from control embryos treated with DMSO or BMS493 (Figure 3B–C’), the
BMS493-treated mutant tails failed to show chondrogenic mesenchymal condensations flanking the
notochord (Figure 3D,D’), indicating that the inhibition of RA signaling only partially rescued the
mutant tails. This finding was not surprising, as survival and expansion of sclerotomal cells, which
form axial chondrogenic condensations, are SHH-dependent [1,44].
RA activity is required for apoptosis-mediated removal of the interdigital mesenchyme [78], and
genetic or teratogenic overactivation of RA signaling is known to induce apoptosis in developing
organs, including the testes, limb mesenchyme, chondrogenic mesenchymal condensations [54], and
the developing tail [65,79]. Loss of SHH signaling in the developing tail causes enhanced apoptosis [42].
Accordingly, the TAM-induced ShhCreERT2/Shhf mutant tails treated with DMSO exhibited increased
numbers of apoptotic cells, as compared to the DMSO-treated tails from control embryos (Figure 3F,H,J).
We also found that BMS493 treatment significantly reduced the number of apoptotic cells in the mutant
tails (Figure 3H–J). These findings strongly suggest that enhanced apoptosis in the mutant tails is at
least partly caused by ectopic activation of RA signaling.
Altogether, our data reveal a hitherto unknown mechanism behind abnormal tail development
upon loss of SHH signaling and strongly suggest involvement of ectopic RA activation in the genesis
of this anomaly. The fact that loss of SHH signaling [42,44] (this study) and ectopic activation of RA
signaling [25,59–65] during tail development generates strikingly similar tail defects further supports
our conclusion.
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SHH-deficient embryos. (A) Timeline representing the induction of CRE-mediated deactivation of 
Shh in embryos and in tail explants. The tails are from E11 control and ShhCreERT2/Shhf mutant 
embryos first exposed in utero to tamoxifen (TAM) at E10 (red arrowhead). All tail explants were 
cultivated in vitro for two days in the presence of 4-hydroxytamoxifen (4-OH-TAM; green 
arrowheads). During the in vitro cultivation period (three days), the tails were treated with DMSO or 
12.5 µM BMS493. The time of harvest of the explants is indicated by a white arrowhead. (B–E) 
Representative Keratin 8 (K8; dark purple) immunostaining visualizing the notochord (no) in 
sections of tail explants from control and mutant embryos. The tails were treated with DMSO (n = 5 
controls and n = 6 mutants) or BMS493 (n = 13 controls and n = 8 mutants). B’–E’ are magnified 
images of the boxed areas in B–E. All the control tails treated with DMSO (B,B’) or BMS493 (C,C’) 
exhibit a notochord and chondrogenic mesenchymal condensations (asterisks in B’ and C’). All the 
DMSO-treated mutant tails lack a notochord in the posterior region, while in the rostral region they 
display an abnormally thin notochord (D,D’). The BMS493-treated mutant tails (E,E’) display a 
notochord (n = 6/8), but fail to exhibit chondrogenic mesenchymal condensations (n = 8/8). (F–I) 
Representative sections of tail explants from control and mutant embryos were immunostained for 
cleaved Lamin A (dark purple) to visualize apoptotic cells. Massive apoptosis in the DMSO-treated 
mutant tails (H; n = 6) as compared to the BMS493-treated mutant tails (I; n = 6) and the 
DMSO-treated (F; n = 3) and BMS493-treated (G; n = 7) control tails. (J) Quantitation of apoptosis in 
Figure 3. In vitro inhibition of retinoic acid signaling partially rescues the tail phenotype of
SHH-deficient embryos. (A) Timeline representing the induction of CRE-mediated deactivation
of Shh in embryos and in tail explants. The tails are from E11 control and ShhCreERT2/Shhf mutant
embryos first exposed in utero to tamoxifen (TAM) at E10 (red arrowhead). All tail explants were
cultivated in vitro for two days in the presence of 4-hydroxytamoxifen (4-OH-TAM; green arrowheads).
D ring the in vitro cultivation period (three days), the tails were treated with DMSO or 12.5 µM
BMS493. The time of harvest of the explants is indicated by a white arrowhead. (B–E) Representative
Keratin 8 (K8; dark purple) immunostaining visualizing the notochord (no) in sections of tail explants
from control and mutant embryos. The tails were treated with DMSO (n = 5 controls and n = 6
mutants) or BMS493 (n = 13 controls a n = 8 mutants). B’–E’ are magnified images of the boxed
areas in B–E. All the control tails treated with DMSO (B,B’) or BMS493 (C,C’) exhibit a notochor
and chondrogenic mesenchymal condensations (asterisks in B’ and C’). All the DMSO-treated mutant
tails lack a notochord in the posterior region, while in the rostral region they display an abnormally
thin notochor (D,D’). The BMS493-treated mutant tails (E,E’) display a notoc ord (n = 6/8), but fail
to exhibit chondrogenic mese chymal condensations (n = 8/8). (F–I) Representative sections of tail
explants from control and mutant mbryos were immunostained for cleave Lamin A (dark purple) to
visualiz apoptotic cells. Massive apoptosis in the DMSO-treated mutant tails (H; n = 6) as compared
to the BMS493-treated mutant tails (I; n = 6) and the DMSO-tre ted (F; n = 3) and BMS493-treat d (G;
n = 7) control tails. (J) Quantitation of apoptosis in tail explants (the number of explants assessed is
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described above). The number of apoptotic cells in the DMSO-treated mutant tails is significantly higher
than in the DMSO-treated (p < 0.005) and BMS493-treated (p = 0.002) control tails. The BMS493-treated
mutant tails show a significant decrease in apoptosis, as compared to the DMSO-treated mutant tails
(p < 0.001). BMS493 had no effects on the extent of apoptosis in the control tails (p = 0.59). Data are mean
values ± standard deviation; **: p < 0.01; ***: p < 0.001. Scale bars: 500 µm (B–E) and 100 µm (B’–I).
2.2. SHH Signaling in the Developing Secondary Palate Is Required to Prevent Enhancement of RA Activity
Development of the secondary palate depends on complex spatio-temporal cellular and molecular
events, and genetic mutations and/or environmental factors that alter these events cause cleft palate,
the most common congenital malformation in humans, with debilitating consequences [80–84]. In mice,
development of the secondary palate begins at E11.5. First, bilateral paired palatal shelves (PS) arise
from the oral side of the maxillary processes and grow downwards while flanking the developing
tongue (E11.5-E14.5). Thereafter, the PS elevate to a horizontal position (E14.5-E15) above the tongue,
and further growth enables the opposing PS to adhere to each other and form a median epithelial
seam which eventually disappears, allowing fusion of the PS [80–84]. The developing palate exhibits
molecular and histological heterogeneity along its anterior-posterior and oral-nasal axes. Along the
oral-nasal axis, this heterogeneity is translated into formation of ciliated respiratory epithelium that
differentiates on the nasal side of the PS, and development of periodic epithelial ridges known as rugae
palatinae in the oral surface of the PS [80,84].
SHH signaling plays a crucial role during PS growth and patterning of rugae palatinae through
regulation of the expression of signaling molecules and transcription factors, and loss of SHH signaling
causes cleft palate [6,80,84–86] and mispatterning of palatal rugae [86]. During palatogenesis, SHH
is produced by the PS epithelium and signals within the PS epithelium and to the PS mesenchyme.
At E11.5 Shh is expressed in the entire epithelium of the emerging PS, and from E12 onwards Shh
expression is restricted to the developing rugae palatinae [86–91].
In the developing palate, RARs are expressed in both the epithelium and mesenchyme [92], whereas,
Cyp26a1 [56] and Cyp26b1 [69,77] are expressed in the epithelium and mesenchyme, respectively.
Interestingly, Cyp26a1 expression is restricted to the oral epithelium of the PS [56], overlapping with Shh
expression [86–91]. Exposure of rodent embryos to excess RA or vitamin A causes cleft palate [61–64,93],
and Cyp26b1n/n mice exhibit cleft palate [68,77] due to failure of elevation of PS [77].
To determine whether ablation of SHH signaling causes enhancement of RA signaling during
palate development, we generated ShhCreERT2/Shhf mutant and control embryos that had been first
exposed to TAM at E10.5-E11 (Figure S1). We found that all the E10.5-E11 TAM-induced ShhCreERT2/Shhf
mutants assessed displayed cleft palate, a defect that was not observed in control embryos (Figure
S2A–F). RT-qPCR revealed that RARg and RARb expression levels were significantly enhanced in the
mutant PS (Figure 4M), indicating enhanced RA activity.
To explore putative sources of RA in the developing palate, we assessed the expression patterns
of RALDH1-3 proteins in TAM-treated control and ShhCreERT2/Shhf mutant embryos. We found that
all three RALDHs were expressed in the developing palate at E13.5 and that their expression patterns
were not altered in the mutant palate (Figure S3). These findings show that RA synthesis occurs in
the developing palate and that enhanced RA signaling in the ShhCreERT2/Shhf mutant palate is not
caused by increased RA synthesis. Interestingly, Cyp26b1 loss-of-function generates cleft palate owing
to enhanced RA signaling and abnormal mesenchymal proliferation in the bend region of the PS [77],
a site that we found to be enriched in RALDH1-3 expression (Figure S3).
Int. J. Mol. Sci. 2019, 20, 2275 10 of 27
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 10 of 27 
 
To determine whether increased RA signaling in the ShhCreERT2/Shhf mutant palate is due to 
decreased CYP26-mediated RA catabolism, we assessed the expression patterns of Cyp26a1, 
Cyp26b1, and Cyp26c1 transcripts in the palate of TAM-treated control and ShhCreERT2/Shhf mutant 
embryos. In both control and mutant embryos, Cyp26b1 displayed a gradient of hybridization 
signals along the anterior-posterior axis of the PS, with highest and lowest intensities seen anteriorly 
and posteriorly, respectively (Figures 4A,B and S4). However, compared to control PS, the 
ShhCreERT2/Shhf mutant PS showed diminished Cyp26b1 hybridization signals (Figures 4 and S4). 
Furthermore, Cyp26a1 hybridization signals were diminished in the epithelium of the mutant PS 
(Figure 4C–H). By contrast, Cyp26c1 expression, which we found to be restricted to subsets of cells in 
rugae palatinae, was unaltered in the mutant PS (Figure 4I,J). Notably, in the control PS, Cyp26a1 
transcripts were enriched in the inter-rugal epithelium (Figure 4C,E,G). Consistent with RARg 
RT-qPCR analysis (Figure 4M), the mutant PS displayed increased RARg hybridization signals in the 
palatal mesenchyme and in the inter-rugal epithelium (Figure 4K–L’). Thus, loss of SHH signaling in 
the developing palate leads to enhanced RA signaling in both the palatal epithelium and palatal 
mesenchyme as a result of loss of Cyp26a1 and Cyp26b1 expression. 
 
Figure 4. SHH signaling in the developing secondary palate is required for expression of Cyp26a1 
and Cyp26b1 to prevent enhancement of retinoic acid signaling. (A–L) Representative developing 
palates from control and ShhCreERT2/Shhf mutant embryos first exposed to tamoxifen (TAM) at 
E10-5-E11. The developmental stages are indicated on the panels. Whole-mount in situ hybridization 
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Figure 4. SHH signaling in the developing secondary palate is required for expression of Cyp26a1 and
Cyp26b1 to prevent enhancement of retinoic acid signaling. (A–L) Representative developing palates
from control and ShhCreERT2/Shhf mutant embryos first exposed to tamoxifen (TAM) at E10-5-E11.
The developmental stages are indicated on the panels. Whole-mount in situ hybridization (WMISH)
with Dig-labelled riboprobes (C,D) and in situ hybridization in parasagittal sections (anterior palatal
region towards the left of the panels) with oligonucleotide probes (A,B,E–L). The inter-rugal epithelium
and rugae palatinae are indicated by arrowheads and arrows, respectively. (A,B) Cyp26b1 expression
in sections of palates (see also Figure S4) from control (A, n = 2) and mutant (B; n = 2) embryos. The
mutant palate shows decreased Cyp26b1 hybridization signals (brown) as compared to the control palate.
(C–H) The mutant palates (D,F,H; n = 3 for WMISH and n = 4 for ISH in sections) show decreased
Cyp26a1 hybridization signals (dark purple in whole-mounts and black in sections) as compared to
control palates (C,E,G; n = 3 for WMISH and n = 4 for ISH in sections). In control palates Cyp26a1
transcripts are enriched in the inter-rugal epithelium. (I,J) Cyp26c1 (black) is expressed in subsets of
cells within the basal layer of rugae palatinae (arrows in I and J) in control (I; n = 2) and mutant (J; n = 2)
palates. (K,L) The mutant palate (L; n = 3) shows increased RARg hybridization signals (brown) in
the mesenchyme and inter-rugal epithelium as compared to the control palate (K; n = 3). K’ and L’
are magnified views of the boxed areas in K and L, respectively. (M) RT-qPCR assay for RARb and
RARg relative to Actb (β-actin) in paired palatal shelves from E13.5 controls (n = 7) and ShhCreERT2/Shhf
mutants (n = 7) first exposed to TAM at E10.5 showing upregulation of RARb (p = 0.004) and RARg
(p = 0.000) in the mutant palatal shelves as compared to the control palatal shelves. Data are mean
values ± standard deviation; **: p < 0.01; ***: p < 0.001. md, mandible; PS, palatal shelf. Scale bars:
500 µm (C,D), 200 µm (K,L), 100 µm (A,B,E–H,K’,L’) and 50 µm (I,J).
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To determine whether increased RA signaling in the ShhCreERT2/Shhf mutant palate is due to
decreased CYP26-mediated RA catabolism, we assessed the expression patterns of Cyp26a1, Cyp26b1,
and Cyp26c1 transcripts in the palate of TAM-treated control and ShhCreERT2/Shhf mutant embryos.
In both control and mutant embryos, Cyp26b1 displayed a gradient of hybridization signals along the
anterior-posterior axis of the PS, with highest and lowest intensities seen anteriorly and posteriorly,
respectively (Figure 4A,B and Figure S4). However, compared to control PS, the ShhCreERT2/Shhf
mutant PS showed diminished Cyp26b1 hybridization signals (Figure 4 and Figure S4). Furthermore,
Cyp26a1 hybridization signals were diminished in the epithelium of the mutant PS (Figure 4C–H).
By contrast, Cyp26c1 expression, which we found to be restricted to subsets of cells in rugae palatinae, was
unaltered in the mutant PS (Figure 4I,J). Notably, in the control PS, Cyp26a1 transcripts were enriched
in the inter-rugal epithelium (Figure 4C,E,G). Consistent with RARg RT-qPCR analysis (Figure 4M),
the mutant PS displayed increased RARg hybridization signals in the palatal mesenchyme and in the
inter-rugal epithelium (Figure 4K–L’). Thus, loss of SHH signaling in the developing palate leads to
enhanced RA signaling in both the palatal epithelium and palatal mesenchyme as a result of loss of
Cyp26a1 and Cyp26b1 expression.
Abrogation of SHH signaling in K14-Cre/Shhf/f mutant mice causes mispatterning of rugae palatinae
manifested as furcations, fusions, and formation of supernumerary rugae [86] similar to those observed
in rat embryos exposed to excess RA [94]. To determine whether, like the K14-Cre/Shhf/f mutants, the
TAM-induced ShhCreERT2/Shhf embryos exhibit mispatterning of rugae palatinae, we immunostained
sections of control and ShhCreERT2/Shhf mutant palates for FOXA1 whose encoding gene is expressed in
rugae palatinae [95] (see also Figure 5A). In the oral epithelium of control palates, FOXA1 was expressed
in the periderm and rugae palatinae (Figure 5B,B’). However, in the ShhCreERT2/Shhf mutant palates,
FOXA1 expression was expanded (Figure 5C,C’), indicating development of supernumerary rugae.
Taken together, these findings show that loss of SHH signaling during palatogenesis leads to enhanced
RA signaling and suggest involvement of enhanced RA signaling in the genesis of cleft palate and
mispatterning of rugae palatinae upon loss of SHH inputs in the developing palate.
Our study revealed a new function for SHH signaling during growth of the PS, which is to keep
RA activity in check in both the palatal epithelium and palatal mesenchyme. It is possible that elevated
RA availability in the palatal epithelium of the TAM-induced ShhCreERT2/Shhf mutant embryos (as a
result of diminished RA degradation by CYP26A1) not only causes enhanced RA signaling within the
palatal epithelium, but also contributes in enhancing RA signaling in the palatal mesenchyme, since
RA is a highly potent and diffusible small molecule. Vice versa, in the TAM-induced ShhCreERT2/Shhf
mutant palates, RA overproduced in the palatal mesenchyme (as a result of diminished RA degradation
by CYP26B1) may also contribute to enhancement of RA signaling in the palatal epithelium.
Nature is replete with repeating, regularly spaced structures such as rugae palatinae, feather and
hair follicles, lingual fungiform papillae, and tracheal cartilage rings. We have shown recently that
antagonistic SHH and RA activities are involved in patterning of the lingual epithelium, whereby SHH
inhibits while RA promotes the formation of taste placodes and lingual glands [40]. Patterning of
rugae palatinae has been shown to involve Turing-based mechanisms, where FGF and SHH function as
activator and inhibitor, respectively [86]. However, how SHH inhibits rugae formation is unknown.
In addition, besides the SHH-FGF signaling pair, other signaling pathways have been incriminated in
patterning of rugae palatinae [86]. In the present study, we confirmed that SHH inhibits the formation
of rugae palatinae, since in the TAM-induced ShhCreERT2/Shhf mutants the palate forms supernumerary
rugae. Furthermore, our findings suggest that RA signaling is involved in patterning of rugae palatinae.
Several lines of evidence support this notion: (1) components of the RA signaling pathway are expressed
in developing rugae palatinae and in the inter-rugal epithelium; (2) Cyp261a1 expression is enriched
in the inter-rugal epithelium; (3) in the inter-rugal epithelium of the ShhCreERT2/Shhf mutant palates
Cyp26a1 expression is severely diminished and RARg expression is enhanced; and (4) loss of SHH
signaling causes abnormal patterning of rugae palatinae [86], this study similar to that engendered by
exposure of the developing palate to excess RA [94]. These findings suggest that RA signaling promotes
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the formation of rugae palatinae and that one mechanism by which SHH inhibits rugae formation is
through the attenuation of RA signaling.
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Figure 5. Loss of SHH signaling in the ShhCreERT2/Shhf mutant palate causes mispatterning of rugae 
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Figure 5. Loss of SHH signaling in the ShhCreERT2/Shhf mutant palate causes mispatterning of rugae
palatinae (A) Bright-field view of a frontal section across the palate of an E13.5 control embryo after in
situ hybridization with a 35S-UTP-labelled Foxa1 riboprobe showing Foxa1 expression (black dots) in
rugae palatinae (arrows). (B,C) Representative FOXA1 immunostaining (dark purple) of para-sagittal
sections of palates (anterior palatal region towards the left of the panels) from E15 control (B; n = 3)
and ShhCreERT2/Shhf mutant (C; n = 3) embryos first exposed to tamoxifen at E10.5-E11. B’ and C’ are
magnified views of the boxed areas in B and C, respectively. In the control palate FOXA1 is detected in
the palatal periderm and in a subset of cells of rugae palatinae. The orthotopic rugae (R) are labelled with
arabic numerals according to the order of their formation as described previously [91]. In the mutant
palate supernumerary rugae (SR) develop between rugae R5 and R6 and between rugae R6 and R7 (C,D).
Scale bars: 200 µm (B,C) and 50 µm (A,B’,C’).
2.3. SHH Signaling Is Required for Cyp26 Expression in Other Developing Structures
To explore whether Cyp26 expression requires SHH inputs in other SHH-dependent developing
structures, such as the genital tubercle and embryonic teeth known to express factors involved in RA
signaling, we analyzed these organs in SHH-deficient and control embryos.
The genital tubercle (GT), primordium of the penis and clitoris, consists of a mesenchyme
covered by ectoderm and a ventral midline structure, the urethral plate epithelium. The urethral
plate epithelium derives from the endoderm of the cloaca and generates the entire penile urethra [96].
Previous work established a crucial role for SHH signaling for normal development of the genitourinary
system, including proximal-distal outgrowth of the GT and formation of the urethral tube [1,97–100].
Shh expression begins in the cloacal membrane before the onset of GT development, and during GT
outgrowth SHH is produced by the urethral plate epithelium and signals to the mesenchyme and
ventral ectoderm of the tubercle [96–98]. Loss of SHH signaling in the developing GT generates various
anomalies, including developmental arrest, hypoplasia due to stunted proximal-distal outgrowth,
and/or hypospadias [97–100].
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Strikingly, rodent embryos exposed to teratogenic doses of vitamin A or RA exhibit GT
anomalies [61], mimicking those caused by loss of SHH signaling [97–100], including GT agenesis
and stunted outgrowth of the GT. Components of the RA signaling cascade are expressed before
and during outgrowth of the GT. Aldh1a2 is expressed in the cloacal membrane and urethral plate
epithelium [48,49,101], all three RARs are expressed in the urethral plate epithelium and in the
mesenchyme of the GT [50,51,102,103], and Cyp26b1 is expressed in the GT mesenchyme [69].
Furthermore, RA activity is readily detectable in the urethral plate epithelium and proximal GT
mesenchyme (Figure 6F).
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 13 of 27 
 
Strikingly, rodent embryos exposed to teratogenic doses of vitamin A or RA exhibit GT 
anomalies [61], mimicking those caused by loss of SHH signaling [97–100], including GT agenesis 
and stunted outgrowth of the GT. Components of the RA signaling cascade are expressed before and 
during outgrowth of the GT. Aldh1a2 is expressed in the cloacal membrane and urethral plate 
epithelium [48,49,101], all three RARs are expressed in the urethral plate epithelium and in the 
mesenchyme of the GT [50,51,102,103], and Cyp26b1 is expressed in the GT mesenchyme [69]. 
Furthermore, RA activity is readily detectable in the urethral plate epithelium and proximal GT 
mesenchyme (Figure 6F). 
 
Figure 6. Loss of SHH signaling in the developing genital tubercle causes downregulation of Cyp26b1 
expression and enhancement of retinoic acid signaling. (A–D) Representative Cyp26b1 whole-mount 
in situ hybridization with riboprobes (purple). E14.5 control (A; n = 2) and ShhCreERT2/Shhf mutant (B; 
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mutant (D; n = 2) embryos first exposed to TAM at E11.5. Diminished Cyp26b1 hybridization signals 
in the genital tubercle (gt) of the mutants. Note that Cyp26b1 signals are not altered in chondrogenic 
condensations within limb buds (lb) of the mutant as these cellular condensations do not express Shh. 
(E) RT-qPCR analysis for RARb and RARg relative to Actb (β-actin) in genital tubercles from E13.5 
Figure 6. Loss of SHH signaling in the developing genital tubercle causes downregulation of Cyp26b1
expression and enhancement of retinoic acid signaling. (A–D) Representative Cyp26b1 whole-mount in
situ hybridization with riboprobes (purple). E14.5 control (A; n = 2) and ShhCreERT2/Shhf mutant (B;
n = 2) embryos first exposed to tamoxifen (TAM) at E12. E13 control (C; n = 2) and ShhCreERT2/Shhf
mutant (D; n = 2) embryos first exposed to TAM at E11.5. Diminished Cyp26b1 hybridization signals
in the genital tubercle (gt) of the mutants. Note that Cyp26b1 signals are not altered in chondrogenic
condensations within limb buds (lb) of the mutant as these cellular condensations do not express Shh.
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(E) RT-qPCR analysis for RARb and RARg relative to Actb (β-actin) in genital tubercles from E13.5
control and ShhCreERT2/Shhf mutant embryos first exposed to TAM at E11.5. Upregulation of RARb
(p = 0.0009) and RARg (p = 0.0002) in the mutant (n = 8 and n = 7 for RARb and RARg, respectively) as
compared to the control (n = 8 and n = 7 for RARb and RARg, respectively) genital tubercles. Data are
mean values ± standard deviation; ***: p < 0.001. (F) β-galactosidase (β-gal) histochemistry revealing
retinoic acid activity in the genital tubercle of control embryos carrying the RAREhsplacZ transgene
(n = 7). Asterisk in F indicates an artefact due to tissue detachment. UPE, urethral plate epithelium.
Scale bars: 300 µm (F) and 500 µm (A–D).
To determine whether Cyp26b1 expression in the GT requires SHH signaling, we compared
the expression of Cyp26b1 in TAM-treated control and ShhCreERT2/Shhf mutant embryos and found
down-regulation of Cyp26b1 expression in the GT of the mutants (Figure 6A–D). As previously
described [97–99], the mutants exhibited hypoplastic GT (Figure 6A–D). Furthermore, RA signaling
was enhanced in the mutant GT as shown by significant enhancement of RARb and RARg expression
levels (Figure 6E). Thus, like in the limb bud [38], in the developing GT SHH inputs are required for
modulating RA activity through maintenance of proper levels of Cyp26b1 expression.
Cyp26b1n/n embryos display enhanced RA signaling in the GT and exhibit a range of anomalies of
external genitalia, including enlarged width due to increased proliferation of the GT mesenchyme [101].
Yet, unlike mouse embryos deficient in SHH signaling [97–100] (this study), the Cyp26b1n/n mutants have
intact proximal-distal outgrowth of the GT [101]. The major function of SHH in the GT mesenchyme is
to maintain proper rates of mesenchymal cell proliferation required for proximal-distal outgrowth [96].
The lack of abnormal proximal-distal outgrowth of the Cyp26b1n/n mutant GT is likely due to that
Cyp26b1 ablation occurs in the presence of a functional Shh gene, a condition that differs from that
of the TAM-induced ShhCreERT2/Shhf mutant GT, in which diminished Cyp26b1 expression occurs in
the absence of SHH inputs. In fact, in Cyp26b1n/n embryos Shh expression in the urethral epithelium
and SHH signaling in the GT mesenchyme were found to be upregulated, as a result of increased RA
signaling [101]. The phenotype of the GT in the Cyp26b1n/n mutants is also different from that of rodent
embryos exposed to teratogenic doses of vitamin A or RA [61], as in the latter the GT fails to form or is
truncated, mimicking the anomalies induced by loss of SHH signaling. A likely explanation for these
differences is that in the Cyp26b1n/n mutants, the GT is exposed to RA emanating from endogenous
sources, leading to upregulation of Shh expression in this organ [101]. By contrast, in embryos exposed
to excess exogenous retinoids the GT is exposed to overwhelming levels of RA. Since teratogenic levels
of RA are known to abolish Shh expression [32,104], it is possible that in the GT of embryos overexposed
to exogenous retinoids, SHH signaling is reduced or lost. Thus, in these embryos, combined loss
of SHH signaling and enhanced RA signaling may lead to conditions resembling those that occur
upon the genetic loss of SHH signaling in the GT. Taken together, these observations suggest that RA
bio-availability must be precisely controlled to ensure normal development of the GT.
Mouse models revealed the importance of SHH signaling during odontogenesis. Loss of SHH
signaling in developing teeth of K14-Cre/Shhn/f, K14-Cre/Smon/f and Evcn/n mutant embryos generates
tooth anomalies, including abnormally small and misshapen teeth with enamel defects [41,105,106]
and failure of differentiation of enamel-producing ameloblasts, epithelial cells that differentiate from
the inner dental epithelium [41,105]. SHH, is produced by the dental epithelium and signals within the
dental epithelium and to the dental mesenchyme [41,105]. Developing teeth express genes encoding
components of the RA pathway, including RALDHs [48,107], CYP26A1 [69], CYP26C1 [67], and
RARs [108]. Remarkably, exposure of mice to excess RA generates enamel defects and abnormal
ameloblast differentiation [109], and in vitro exposure of embryonic mouse teeth to supraphysiological
levels of RA leads to formation of misshapen teeth [110]. However, physiological levels of RA seem to
be required for normal tooth formation, since vitamin A deficiency in rats causes a range of defects,
including enamel hypoplasia, abnormal dentine formation, and metaplasia of dental epithelia [111–113].
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We found that developing teeth from K14-CRE/Shhf/f mutant mice exhibit severe downregulation of
Cyp26a1 and Cyp26c1 expression levels in the inner dental epithelium (Figure 7). However, compared
to control teeth that showed an absence of Cyp26b1 expression in the dental papilla mesenchyme
(Figure 7C,C’), consistent with previous findings [69], the mutant teeth exhibited ectopic Cyp26b1
hybridization signals in this tissue (Figure 7D,D’). By contrast, Cyp26b1 expression in osteoblast
progenitors, including in the developing alveolar bone at the periphery of developing teeth [69], was
as expected unaltered in the mutants (Figure 7C,D) as these cells do not express Keratin 14 and SHH.
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Figure 7. SHH signaling is required for maintenance of the expression of Cyp26a1 and Cyp26c1 in the
developing tooth. (A–F). Representative Cyp26a1 (A,B; n = 2 controls and n = 2 mutants), Cyp26b1 (C,D;
one control and one mutant) and Cyp26c1 (E,F; n = 2 controls and n = 2 mutants) in situ hybridization
(black) with oligonucleotide probes in frontal sections across developing first molars from control (A,C,E)
and K14-CRE/Shhf/f mutant (B,D,F) newborn (P0) mice. C’ and D’ are magnified views of the boxed areas
in C and D, respectively. The mutant molars show severely diminished Cyp26a1 hybridization signals in
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the inner dental epithelium (IDE) and abolished Cyp26a1 expression in cells of the stellate reticulum
(SR). Note also the severely reduced domain of Cyp26c1 expression in the IDE of the mutant tooth (arrow
in F). The mutant molars (D) exhibit ectopic expression of Cyp26b1 in the dental papilla mesenchyme
(DP). Cyp26b1 expression in cells of the developing alveolar bone (arrowheads in C and D) is unaltered
in the mutant. Scale bars: 100 µm (A–D,E,F) and 50 µm (C’,D’).
The dependence of Cyp26b1 expression on SHH signaling seems to be context-dependent. While
loss of SHH signaling in the developing limb [38], genital tubercle, and palate (this study) leads to
diminished levels of Cyp26b1 expression, Cyp26b1 transcript levels are enhanced in tongue mesenchyme
of SHH-deficient embryos [40] (see also Figure S4), and Cyp26b1 is expressed ectopically in the dental
papilla mesenchyme of K14-CRE/Shhf/f mutant molars.
2.4. Conclusions
Previous studies in the embryonic limb [38] and tongue [40] together with our present findings
in several developing structures showed that SHH signaling abates RA signaling through the
maintenance/reinforcement of Cyp26 expression. Thus, during development of various organs,
SHH uses this same strategy to antagonize RA signaling. Furthermore, loss of SHH signaling in
the developing tongue [40], tail, secondary palate, genital tubercle, and tooth (this study) causes
these structures to develop defects that are remarkably akin to those engendered by genetically or
pharmacologically induced overactivation of RA signaling. A literature search revealed strikingly
similar congenital anomalies caused by deregulation of Hedgehog and RA signaling (Table S1),
suggesting that antagonism between the two pathways may be a common phenomenon.
It is unlikely that SHH directly induces the initial expression of Cyp26 transcripts, since experiments
showed that the Smoothened agonist SAG reinforces Cyp26a1 expression in Cyp26a1-expressing tissues
but fails to induce de novo expression of this gene in Cyp26a1-non-expressing tissues [40] (this study).
Which factor(s) whose activities are modulated by SHH signaling directly regulate Cyp26 expression,
and thus RA activity, remain to be identified.
Delineating how cell signaling cascades interact to control tissue patterning, cell fate specification
and organogenesis is key to understanding the etiopathogenesis of congenital malformations and
malignancies, and knowledge of developmental pathway interactions constitutes a basis for regenerative
medicine. Our findings in the developing tail provide a probable, mechanistic explanation for the tail
anomalies engendered by loss of SHH signaling, that is, involvement of aberrant enhancement of RA
signaling in the genesis of these malformations.
Human embryos develop a tail bud and a transient tail, the latter being normally fated to
regress [114,115] through apoptosis [116]. A congenital midline malformation known as “human
tail” [114,117–119] has been suggested to result from failure of regression of the embryonic tail [115].
Currently, the etiology of “human tail” and underlying molecular mechanisms leading to this anomaly
are unknown. Our findings in mouse embryos not only provide insights into the interplay between
signaling pathways in the control of development of the caudal region of the embryo, but also provide
valuable information for future work aiming at deciphering the etiopathogenesis of “human tail”.
Besides their role in tissue patterning, the Hedgehog and RA pathways play crucial roles during
organogenesis and postnatal tissue homeostasis. Compelling evidence suggests that Hedgehog
signaling promotes cell proliferation and cell survival [1,19], whereas RA inhibits cell proliferation
and induces differentiation and/or apoptosis [3,54,65,78,79,120]. In human multiple myeloma, a B
cell malignancy, SHH derived from myeloma plasma cells has been shown to antagonize RA activity
through upregulation of CYP26A1 [39]. Altogether these observations prompt the question of whether
in other tumor types in which Hedgehog signaling is pathologically upregulated [17,18,121], RA
signaling is mitigated through Hedgehog-dependent CYP26-mediated clearance of RA, providing
favorable conditions for growth and survival of tumor cells.
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3. Materials and Methods
3.1. Ethics Statement
The procedures involving the use of mice were reviewed and approved by the Animal Research
Ethics Committee in Göteborg, Sweden (Dnr. 230-2010 (29 September 2010), 174-2013 (12 November
2013) and 40-2016 (27 April 2016)). Mouse experiments were also carried out under approved protocols
in strict accordance with the policies and procedures established by the University of California,
San Francisco (UCSF) Institutional Animal Care and Use Committees (UCSF protocol AN084146
re-approved on 05 March 2019).
3.2. Mouse Lines
The K14-CRE/Shhf/f mutant, the ShhGFPCRE/Smof/f mutant, the tamoxifen (TAM)-inducible
ShhCreERT2/Shhf mutant, and the Shhn/n mutant embryos as well as their control littermates were
generated and identified as described previously [40–43]. Control and ShhGFPCRE/Smof/f mutant
embryos carrying the RAREhsplacZ transgene [73] were generated as described [40]. For CRE-mediated
ablation of Shh in ShhCreERT2/Shhf embryos, pregnant females were treated with intraperitoneal
injections of TAM every other day (excluding the day of embryo harvest) as described [40].
3.3. Histology, Immunohistochemistry, In Situ Hybridization, β-Galactosidase Histochemistry and RT-qPCR
Tissues and organs were processed for histology (Alcian blue van Gieson staining),
immunohistochemistry, in situ hybridization, and β-galactosidase histochemistry as described
previously [40]. Rabbit antibody targeting cleaved Lamin A (small subunit; 1:1000 dilution) was
obtained from Cell Signaling Technology (Danvers, MA, USA). Rabbit monoclonal (MAB) antibody
against FOXA1 (1:5000 dilution) was from Abcam (Cambridge, UK). For detection of Cyp26b1 and
Cyp26c1 transcripts in tissue sections, oligonucleotide probes targeting Mm-Cyp26b1 (NM_175475.3;
target sequence: 460-1308) and Mm-Cyp26c1 (NM_001105201.1; target sequences: 21-1134) were used.
For RT-qPCR assays, the entire tail per embryo, the entire genital tubercle per embryo, and a pair of
palatal shelves per embryo were analyzed. Actb (β-actin) was used as a reference gene for RT-qPCR
data. Primers and conditions for RT-qPCR, other probes used for in situ hybridization, and other
antibodies have been described [40].
3.4. In Vitro Explant Cultures and Quantification of Apoptosis
Shhf/f females were mated with ShhCreERT2 males. The pregnant females received an intraperitoneal
injection of TAM [40] to induce in utero CRE-mediated Shh deactivation at embryonic day 10 (E10).
The next day (E11), tails/pelvic girdles were dissected from control and ShhCreERT2/Shhf mutant embryos
and cultivated in vitro in an organ culture system as described previously [40]. The medium contained
2.5 and 1.25 µM 4-OH-TAM (4-Hydroxytamoxifen, Sigma-Aldrich, Stockholm, Sweden) during the first
and second days of culture, respectively, to enable continuation of CRE-mediated ablation of Shh in vitro.
The explants were cultivated for a total period of 3 days in the presence of vehicle control (DMSO) or
12.5 µM BMS493, a pan-RAR inverse agonist (Tocris Bioscience, Abingdon, UK). Thereafter, the explants
treated with DMSO or BMS493 were processed for Keratin 8 immunohistochemistry. For quantification
of apoptosis, sections of tail explants cultivated as described above were processed for immunostaining
for cleaved Lamin A to visualize apoptotic cells. Apoptotic epithelial and mesenchymal cells in sections
of tail explants from controls and ShhCreERT2/Shhf mutants were counted in the caudal portion of the
tail through a ×20 objective. Student’s t-test was used for statistical analysis.
For Cyp26a1 whole-mount in situ hybridization, tails/pelvic girdles were dissected from E11.5
control embryos and cultivated for 24 h in vitro under conditions described previously [40] in the
presence of DMSO or 0.2 µM SAG, a small molecule agonist of Smoothened [122].
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